The PREVENTION-ACHD study is a prospective observational trial designed to validate a novel risk score model for predicting sudden cardiac death in adults with congenital heart disease.
Observational (n=660)
No
Can a novel risk score model and current guideline recommendations accurately predict sudden cardiac death in adults with congenital heart disease?
The PREVENTION-ACHD study aims to prospectively validate a new risk score model for primary prevention of sudden cardiac death in adults with congenital heart disease.
BACKGROUND: Many adult congenital heart disease (ACHD) patients are at risk of sudden cardiac death (SCD). An implantable cardioverter-defibrillator (ICD) may prevent SCD, but the evidence for primary prevention indications is still unsatisfactory. STUDY DESIGN: PREVENTION-ACHD is a prospective study with which we aim to prospectively validate a new risk score model for primary prevention of SCD in ACHD patients, as well as the currently existing guideline recommendations. Patients are screened using a novel risk score to predict SCD as well as current ICD indications according to an international Consensus Statement. Patients are followed up for two years. The primary endpoint is the occurrence of SCD and sustained ventricular arrhythmias. The Study was registered at ClinicalTrials.gov (NCT03957824). CONCLUSION: PREVENTION-ACHD is the first prospective study on SCD in ACHD patients. In the light of a growing and aging population of patients with more severe congenital heart defects, more robust clinical evidence on primary prevention of SCD is urgently needed.
Vehmeijer et al. (Wed,) conducted a observational in Adult Congenital Heart Disease (n=660). High risk of sudden cardiac death (≥3% annual risk by novel risk score) vs. Low risk of sudden cardiac death (<3% annual risk) was evaluated on Composite of sudden cardiac death or sustained ventricular arrhythmia at two years of follow-up. The PREVENTION-ACHD study is a prospective observational trial designed to validate a novel risk score model for predicting sudden cardiac death in adults with congenital heart disease.